Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.

Should tacrolimus dose be reduced upon posaconazole initiation in transplant patients?

23 Dec 2019

A recent study has proven the feasibility of an empiric 50-percent dose reduction of oral tacrolimus to 0.03 mg/kg/day when used together with posaconazole to achieve therapeutic levels in patients receiving an allogeneic stem cell transplant.

This retrospective chart review at an academic medical centre sought to determine whether tacrolimus doses should be reduced upon initiation of posaconazole in allogeneic stem cell transplant patients. All transplant recipients who were treated with concomitant posaconazole and tacrolimus from February 2016 through December 2017 were included in the analysis.

An internal electronic database was used to identify 79 patients. Those who did not receive an empiric dose reduction had significantly longer median time to therapeutic tacrolimus concentration (dose reduction: 0 percent, 10 d; 1–30 percent, 4 d; 31–65 percent, 5 d; >65 percent, 4 d; p=0.0395).

Patients who did not receive an empiric dose reduction also had the highest rate of supratherapeutic levels, which was found to be substantial compared to those receiving 31–65-percent dose reduction (p<0.001).

Posaconazole lowers the risk of invasive Aspergillus in transplant recipients, according to the investigators. However, it also significantly inhibits tacrolimus metabolism.

“One study demonstrated that a threefold dose reduction of tacrolimus was required to obtain therapeutic concentrations when used with posaconazole,” they said. “However, with empiric dose reduction, there is a risk of subtherapeutic tacrolimus levels and subsequent graft failure or graft-versus-host disease.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.